Key result
Treatment with the HDAC3-selective inhibitor RGFP966 induced thermogenic gene expression in murine and human fat cultures, an effect that was blunted in the absence of PRDM16.
Population
Murine and human fat cultures
Design
Preclinical
Authors
Loading...
Does not support clinical use in obesity; hypothesis-generating for PRDM16-dependent thermogenesis as a therapeutic target.
HDAC3-selective inhibition activates thermogenic gene expression in brown and beige fat via PRDM16, suggesting a potential therapeutic target for obesity and metabolic disorders.
Liao et al. (2018) studied obesity and metabolic disorders. HDAC3-selective inhibitor RGFP966 was evaluated on thermogenic gene expression. Treatment with the HDAC3-selective inhibitor RGFP966 induced thermogenic gene expression in murine and human fat cultures, an effect that was blunted in the absence of PRDM16.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: